Synthetic Lethality of PARP Inhibitors in Prostate Cancer

In this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer.

Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: Emmanuel Antonarakis, MD Tags: Genitourinary Cancers News Prostate Cancer Source Type: news